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Abstract
Background: Human papillomavirus (HPV) vaccination targeting females 12–13 years commenced in Australia in
2007, with catch-up of females 13–26 years until the end of 2009. No analyses of HPV vaccination program impact
by either socioeconomic or geographic factors have been reported for Australia.
Methods: Hospital admissions between July 2004-June 2011 involving a diagnosis of genital warts were obtained
from a comprehensive national database. We compared sex- and age-specific admission rates in July 2006–June
2007 (pre-vaccination period) and July 2010–June 2011 (post-vaccination period) according to Index of Relative
Socio-economic Disadvantage, nationally and stratified by remoteness area relating to the individual’s area of
residence, using Poisson/ negative binomial models.
Results: Admission rates per 100,000 population in females aged 10–19 years (predominantly vaccinated at school),
reduced from 42.2 to 6.0 (rate reduction 86.7 %; 95 % CI:82.2–90.0 %) in more disadvantaged areas and from 26.8 to
4.0 (85.0 %; 95 % CI:79.7–88.9 %) in less disadvantaged areas. In females aged 20–29 years (predominantly vaccinated
in the community), the decreases were from 73.9 to 26.4 (66.0 %; 95 % CI:57.7–72.6 %) and from 61.9 to 23.8 (61.6 %;
95 % CI:52.9–68.7 %) in more and less disadvantaged areas, respectively. The reductions were similar in more vs
less disadvantaged areas both inside major cities (88.6 %; 95 % CI: 82.2–92.7 % vs 87.9 %; 95 % CI:82.6–91.6 % in
females aged 10–19 years; 64.0 %; 95 % CI:57.0–69.9 % vs 63.8 %; 95 % CI:52.9–72.1 % for females aged 20–29
years) and outside major cities (88.8 %; 95 % CI: 83.7–92.3 % vs 85.8 %; 95 % CI:73.5–92.4 % in females aged 10–
19 years; 71.1 %; 95 % CI:58.8–79.7 % vs 67.6 %; 95 % CI:48.2–79.8 % for females aged 20–29 years). Admission
rates in males aged 20–29 years also reduced, by 23.0 % (95 % CI:4.8–37.8 %) and 39.4 % (95 % CI:28.9–48.3 %)
in more versus less disadvantaged areas respectively.
Conclusions: The relative reduction in genital warts appears similar in young females across different levels of
disadvantage, including within and outside major cities, both for females predominantly vaccinated at school and
in the community.
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Background
A publicly-funded vaccination program against human
papillomavirus (HPV) commenced in Australia in 2007,
initially targeting 12–13 year old females and from 2013
including males aged 12–13 years. The National HPV
Vaccination Program (NHVP) included catch-up pro-
grams for school-aged girls (12–17 years; delivered
through schools in 2007 and 2008), young women (18–
26 years; delivered in community settings until end-
2009) and school-aged boys (14–15 years, delivered
through schools in 2013 and 2014). The quadrivalent
vaccine listed for use within the NHVP (Gardasil®,
Merck&Co., Whitehouse Station, NJ USA) provides pro-
tection against HPV 16, 18, 6 and 11. HPV 16 and 18
are associated with approximately 78 % of cervical can-
cers in Australia [1], and HPV 6 and 11 are associated
with approximately 90 % of genital warts [2].
Comparisons of vaccine uptake from the first target
age-group of young females (aged 12–13 years in 2007)
across different socioeconomic groups and remoteness
areas of Australia estimated three-dose vaccine uptake
was 71.5 % in the most disadvantaged areas versus
75.6 % in the least disadvantaged areas, and ranged from
70.1 % in remote areas to 73.6 % in major cities [3]. Less
is known about the school or community-based
catch-up programs. However initial studies from two
Australian jurisdictions suggest uptake in young
women was lower in more disadvantaged areas than
in less disadvantaged areas [4, 5], and lower in inner
regional areas than in either major cities or outer re-
gional and remote areas [5].
To date there are no corresponding data on NHVP
impact in Australia by socioeconomic status (SES) or
geographic factors. Therefore, the aim of this study was
to compare the impact of the NHVP in Australia on
genital warts hospitalisations according to socioeco-
nomic and geographic factors, both in females vacci-
nated at school and in the community. The indirect
impact on genital warts hospitalisations in males ac-
cording to socioeconomic and geographic factors was
also examined.
Material and methods
Data sources
Data from the National Hospital Morbidity Database
(NHMD), a comprehensive census of admissions to vir-
tually all public and private hospitals in Australia, were
obtained from the Australian Institute of Health and
Welfare. Recorded data include information on the age,
sex, geographic area of residence and Indigenous status
of the individual; date of admission; primary and any
contributing diagnoses; and any procedures performed.
The current analysis includes all admissions with a
primary or contributing diagnosis coded with the
International Classification of Diseases (ICD-10) code
A63.0 (anogenital warts) between 1 July 2004 and 30
June 2011, in females and males aged 10–39 years at ad-
mission. Population estimates were sourced from the
Australian Bureau of Statistics website [6].
Age groups
Admissions and population estimates were stratified by
sex and classified into three age groups based on likely
exposure to HPV vaccination and delivery method in
females from 2007 onwards, with those 10–19 years cor-
responding to those predominantly offered vaccination
at school, those 20-29 years predominantly offered vac-
cination in the community, and those 30–39 years not
offered vaccination through the public program.
Socioeconomic status (SES)
Data from the Australian Census are used to create a
standard suite of indices which rank geographic areas
according to different measures of socioeconomic disad-
vantage based on characteristics of residents within that
area, for example measures of income, unemployment,
occupation skill level and aspects of housing [7, 8].
Admissions and population data were classified based on
the Statistical Local Area (SLA; the smallest area for
which socioeconomic, health and population are avail-
able) of usual residence and that area’s corresponding
Index of Relative Socioeconomic Disadvantage (IRSD)
ranking, using published data [7]. Areas within IRSD
deciles 1–5 were categorised as more disadvantaged,
while areas within IRSD deciles 6–10 were categorised
as less disadvantaged.
Remoteness area of residence
Admissions and population data were also classified as
resident inside or outside major cities, according to a
published mapping between SLA and the Remoteness
Area structure of the Australian Standard Geographical
Classification [9], which is based on the physical road
distance of the location to urban centres of different
sizes [10]. As there is some correlation between the re-
moteness and socioeconomic index of areas (people liv-
ing in more disadvantaged areas are under-represented
in major urban areas but over-represented in smaller
towns and remote areas) [11], this classification was
used for stratifying analyses of SES.
Statistical analyses
Consistent with previous analyses of this data [12], Pois-
son and negative binomial regression were used to assess
overall change in admission rates between the last pre-
vaccination year (July 2006–June 2007; hereafter 2006/
2007) and the most recent data available (July 2010–
June 2011; hereafter 2010/2011), by age group and sex.
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Interaction terms were used to examine whether any ob-
served variation in admission rates since 2006/2007 dif-
fered by socioeconomic status.
A secondary analysis was performed, using admission
rate ratios, comparing admission rates in each successive
twelve-month period from 1 July 2007 onwards to the
three-year average pre-vaccination admission rate (1 July
2004–30 June 2007). Due to the comparatively high level
of missing data for remoteness area in July 2004–June
2005 (~22 %; <1 % thereafter) and SES in July 2004–June
2006 (~25 %; <1 % thereafter), the admission rate ratio
was not used as the main analysis.
In order to assess whether missing data for remoteness
area and SES might have biased the results, in both cases
an overall analysis was done by age as in previous work
[12], but restricted only to those admissions where re-
moteness area/ SES data were not missing.
Additional subgroup analyses
Cervical screening: Approximately 23 % of warts admis-
sions in females aged 10–39 years involved a procedure
related to investigation or treatment of screen-detected
cervical abnormalities (“screening follow-up”; Additional
file 1: Table S1). Participation in cervical screening in
Australia varies by SES (but relatively little by remote-
ness area) [13]; to exclude the possibility that variations
in cervical screening behaviour between subgroups influ-
enced the findings, we undertook a sensitivity analysis
where “screening follow-up” admissions were excluded.
Men who have sex with men (MSM): As in a previous
analysis [12] we examined trends in male admissions
stratified according to whether the admission involved
a diagnosis or procedure code associated with anal
warts, or whether only non-anal sites were recorded
(Additional file 1 Table S1), since anal HPV infections
Table 1 Admissions involving a diagnosis of genital warts by sex, age, socioeconomic status and area of residence, July 2004–June 2011
More disadvantageda Less disadvantageda
Females
10–19 years 947 746
(excl. screening follow-upb) 784 573
20–29 years 2,061 2,610
(excl screening follow-upb) 1,594 1,955
30–39 years 1,034 1,308
(excl screening follow-upb) 834 1,020
Males
10–19 years 118 144
20–29 years 956 1,636
(anal site involvedc) 429 798
(anal site NOT involvedc) 436 645
30–39 years 654 1,146
Major citiesd Other areasd
More disadvantaged Less disadvantaged More disadvantaged Less disadvantaged
Females
10–19 years 349 563 598 183
20–29 years 984 2,171 1,077 439
30–39 years 561 1,123 473 185
Males
20–29 years 506 1,402 450 234
(anal site involvedc) 257 699 172 99
(anal site NOT involvedc) 196 532 240 113
30–39 years 376 1,004 278 142
aBased on the Index of Relative Socioeconomic Disadvantage of the admitted individual’s area of residence [7, 8]. bAdmissions involving a procedure related to
follow-up of cervical screening were excluded from this sub-analysis (see Additional file1: Table S1) cAdmissions were stratified according to whether the admis-
sion involved a diagnosis or treatment procedure code associated with anal warts, or whether only non-anal sites were recorded (Additional file1: Table S1); admis-
sions where the warts site could not be ascertained were excluded from this sub-analysis dBased on the Australian Standard Geographical Classification (ASGC)
remoteness area of the admitted individual’s area of residence [10]. “Other areas” includes the ASGC categories Inner Regional, Outer Regional, Remote and Very
Remote. In cases where the NHMD did not record remoteness area (RA) for an admission, this was assigned based on a standard Australian Bureau of Statistics
(ABS) mapping for the admitted individual’s SLA [9]. In cases where that SLA contained locations with different levels of remoteness, the admission was assigned
according to the standard ABS weighting for each remoteness area within the SLA [9]
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and HPV-related disease generally are more common
in MSM [14, 15]. Admissions where the warts site
could not be ascertained were excluded from this
sub-analysis.
Ethical approval statement
Ethics approval for this study was granted by the Univer-
sity of Sydney Human Research Ethics Committee.
Results
Table 1 shows the distribution of admissions included in
the analysis by sex, age group, SES and remoteness area.
Socioeconomic status
Annual admission rates by age, sex and SES are shown
in Fig. 1 (national) and Fig. 2 (inside versus outside
major cities). Significant reductions in admissions in-
volving a diagnosis of genital warts since 2006/2007
were observed for females aged 10–19 and 20–29 years,
and males aged 20–29 years, with the greatest reductions
observed in females aged 10–19, followed by those 20–29
and then males 20–29 years (Table 2).
In females, percentage reductions did not differ signifi-
cantly between those living in more versus less disadvan-
taged areas, either for females aged 10–19 years at
admission (predominantly vaccinated at school) or 20–
29 years at admission (predominantly vaccinated in the
community) (Table 2). Similar patterns were observed
when admissions were stratified by residence inside ver-
sus outside major cities, with significant reductions in
admissions observed across all subcategories of females
aged 10–19 years and 20–29 years, but not in females
30–39 years. There was no evidence of an interaction
between SES and the change in admission rates over
time in females in any age group, inside or outside
major cities.
In males aged 20–29 years, admission rates decreased
since 2006/2007 both in more and less disadvantaged
areas, with no evidence of an interaction between SES and
the change in admission rates (Table 2). The findings var-
ied for 20–29 year old males residing in major cities, how-
ever, where there was evidence of an interaction between
SES and the change in admission rates (Pinteraction = 0.02),
with a significant reduction observed in less disadvan-
taged, but not more disadvantaged areas of major cities.
There were some significant reductions in estimated admis-
sion rates for males by particular subgroupings (for example
males aged 20–29 years living outside major cities in more
disadvantaged areas) but there was no consistent pattern
and no other evidence of interaction between SES groups.
The findings based on the admission rate ratio were
very similar to the main analysis findings (Figs. 3 and 4).
Significant reductions were observed in all subcategories
for females aged 10–19 years and 20–29 years (but not
in females or males aged 30–39 years). Nationally, re-
ductions in males aged 20–29 years were significant in
both more and less disadvantaged areas.
Additional analyses
The observed patterns in females aged 10–19 and 20–29
years did not alter when admissions relating to cervical
screening follow-up were excluded from the analysis.
The estimated reductions within an age group did not
differ significantly by SES, and the estimated reductions
for each subgroup were broadly similar regardless of
whether admissions relating cervical screening follow-up
were included or not (Additional file 1: Table S2).
When admissions in males aged 20–29 years were
stratified based on whether or not anal site was in-
volved, the estimated reductions in admissions not in-
volving anal site were substantial and significant, and
did not differ by SES; however admissions involving
anal site did differ by SES and only reduced in less
disadvantaged areas (Additional file 1: Table S2). As
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Fig. 1 Admissions involving a diagnosis of genital warts (per 100,000
population), by age and socioeconomic status, in a) females and b)
males. Males aged 10–19 years were excluded due to the small
number of admissions
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there were apparent interactions by SES in males
aged 20–29 years both in major cities and for anal
warts, an additional analysis examined admissions in
this age group in major cities, stratified by site. The
interaction by SES for males this age residing in
major cities appeared to be driven by differences in
anal warts (Pinteraction < 0.01), whereas there was a
substantial and significant reduction in admissions in-
volving only non-anal sites which did not differ by
SES (Additional file 1: Table S2).
In overall analyses by age, as undertaken in pre-
vious work [12] but restricted to those admissions
where SES/ remoteness area data were not missing,
we found that the estimated reductions in the
admission rate did not significantly differ from the
original estimates based on the full set and reported
in the previous analysis [12], but both the remote-
ness subset and the SES subset tended to result in
lower point estimates of the reduction (Additional
file 1: Figure S1).
Fig. 2 Admissions involving a diagnosis of genital warts (per 100,000 population), by age, socioeconomic status and remoteness area of
residence. a Females 10–19 years; b Females 20–29 years; c Females 30–39 years; d Males 20–29 years; e Males 30–39 years
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Discussion
In a previous analysis of this data, we found that the rate
of genital warts admissions had decreased in school-
aged girls (12–17 years), and in both young women and
men (18–26 years) since the introduction of the NHVP
[12]. In this further analysis, we found these reductions
appear to be similar across different socioeconomic
groups for teenaged-girls (10–19 years) and young
women (20–29 years), and generally also for young men
(20–29 years), residing both inside and outside major
cities. This is the first study in Australia to examine HPV
vaccine impact within subgroups based on socioeconomic
Table 2 Admission rates and estimated post-vaccination program reductions, by sex, age, socioeconomic status and area of residence
Group Admission rate per 100,000a Overall reduction July 2006-June 2007
to July 2010-June 2011 % (95% CI)
Interaction
term P valuebJuly 2006-June 2007 July 2010-June 2011
Females 10–19 years
Nationalc More disadvantaged 42.16 6.03 86.7 (82.2, 90.0)
Less disadvantaged 26.75 3.96 85.0 (79.7, 88.9) 0.57
Major citiesd More disadvantaged 31.13 3.62 88.6 (82.2, 92.7)
Less disadvantaged 23.73 3.16 87.9 (82.6, 91.6) 0.83
Other areasd More disadvantaged 56.47 7.05 88.8 (83.7, 92.3)
Less disadvantaged 42.11 5.36 85.8 (73.5, 92.4) 0.52
Females 20–29 years
National More disadvantaged 73.93 26.39 66.0 (57.7, 72.6)
Less disadvantaged 61.87 23.82 61.6 (52.9, 68.7) 0.61
Major citiesd More disadvantaged 57.05 16.62 64.0 (57.0, 69.9)
Less disadvantaged 60.81 23.35 63.8 (52.9, 72.1) 0.09
Other areasd More disadvantaged 105.01 34.28 71.1 (58.8, 79.7)
Less disadvantaged 70.29 20.34 67.6 (48.2, 79.8) 0.71
Females 30–39 years
National More disadvantaged 27.72 28.67 1.7 ( −20.4, 19.7)
Less disadvantaged 22.50 23.72 −9.4 ( −30.9, 8.5) 0.44
Major citiesd More disadvantaged 25.50 22.04 14.1 (−13.9, 35.1)
Less disadvantaged 23.11 21.80 1.8 (−19.4, 19.2) 0.45
Other areasd More disadvantaged 31.18 29.25 17.2 (−13.5, 39.6)
Less disadvantaged 18.52 21.02 −5.6 (−77.2, 37.1) 0.43
Males 20–29 years
National More disadvantaged 25.95 19.17 23.0 (4.8, 37.8)
Less disadvantaged 36.69 20.28 39.4 (28.9, 48.3) 0.08
Major citiesd More disadvantaged 20.27 17.47 16.5 (−11.1, 37.3)
Less disadvantaged 37.81 18.96 43.7 (33.0, 52.6) 0.02
Other areasd More disadvantaged 36.28 18.61 42.6 (19.4, 59.1)
Less disadvantaged 28.23 24.38 23.5 (−19.5, 51.0) 0.32
Males 30–39 years
National More disadvantaged 16.63 16.44 7.5 (−19.8, 28.5)
Less disadvantaged 24.44 18.56 26.0 (10.1, 39.1) 0.18
Major citiesd More disadvantaged 16.94 15.75 6.4 (−30.9, 33.1)
Less disadvantaged 25.32 18.84 29.0 (12.7, 42.3) 0.17
Other areasd More disadvantaged 16.14 14.22 32.2 (−5.0, 56.2)
Less disadvantaged 18.76 15.75 13.0 (−61.8, 53.3) 0.52
Significant reductions between July 2006–June 2007 and July 2010-June 2011 in bold. aAdmission rate per 100,000 individuals in the population bP value for
whether the effect of time on admission rates (if any) differed by SES (ie P value for model interaction term) cSES: socioeconomic status, based on the Index of
Relative Socioeconomic Disadvantage of the admitted individual’s area of residence [7, 8] d Remoteness of admitted individual’s area of residence, based on the
Australian Standard Geographical Classification [10]
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or geographic factors, and one of only a small number of
studies internationally to have examined vaccine impact
within sociodemographic subgroups of females [12, 16].
Our findings that reductions in teenaged-females were
very similar across different socioeconomic areas, includ-
ing inside and outside major cities, is consistent with
initial estimates of vaccine uptake from the first target
age-group of young females (aged 12–13 years in 2007)
Fig. 3 Admission rate ratio (relative to pre-vaccination mean) by age, SES and remoteness area of residence (females). a and b 10–19 years; c and
d 20–29 years; e and f 30–39 years
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which reported that uptake was relatively equal across
these different groups [3]. Similar national data are not
available for young women who accessed the vaccine
through primary care, as the NHVP Register data is
known to under-report uptake in this group [17], however
data from two states suggest some potential differences.
Based on data extracted from the NHVP Register for
women residing in Victoria, three-dose uptake was re-
ported as 33.4 % in the most disadvantaged areas and
38.0 % in the least disadvantaged areas [4], and in a NSW-
based study of young women with a recent negative cer-
vical screening test, self-reported uptake of one or more
vaccine doses was associated with higher socioeconomic
status and living outside inner regional areas [5]. We
found no significant difference in the estimated reductions
between women living in more versus less disadvantaged
areas, although the cohorts which we examined differ
slightly from those examined in the Victorian (females
aged 18–26 years in 2007) and the NSW (females both
aged 20–29 in 2008–2009 and 26 years or younger in mid-
2007) studies. The last year of data examined here includes
those aged 20–29 in July 2010-June 2011, who were poten-
tially aged from 16–26 in mid-2007. The inclusion of
slightly younger cohorts (aged 16–17 in 2007; predomin-
antly offered vaccination at school) may potentially weaken
differences in uptake between more and less disadvantaged
areas if these differences were smaller in the school-based
catch-up than in the community (in the youngest age
group vaccinated at school, dose 1 uptake differed by only
1.2 % which is smaller than differences in the Victorian
and NSW studies) [3–5]. Additionally the SES associ-
ated with the area of residence of these younger
Fig. 4 Admission rate ratio (relative to pre-vaccination mean) by age, SES and remoteness area of residence (males). a and b 20–29 years;
c and d 30–39 years
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cohorts of women at the time of their hospital admis-
sion may not be the same as it was when they were
vaccinated, as young women could have moved since
that time. Furthermore as our results are for impact,
they may not reflect exactly the same patterns as
uptake, due to indirect protection effects [18]. Our
finding that reductions in young men were also very
similar across different socioeconomic areas, including
inside and outside major cities, is also reassuring. An
identified difference in the relative reduction in young
men by SES within major cities appeared to be driven
by differences in anal warts. No difference was ob-
served in admissions involving only non-anal sites,
which may more closely reflect indirect protection
from female-only vaccination if MSM are over-
represented in admissions involving anal warts.
A major strength of this study is that it uses data
from a large, comprehensive and routinely-collected
national dataset.
A limitation of this study is that is ecological, and
vaccination status of admitted individuals is not known.
However, an analysis of the same data over a longer
period found the substantial reductions in admissions
involving genital warts since mid-2007 were confined to
young females and males, and the observed reduction
did not appear to be a continuation of a pre-existing
decline in either group [12]. This study is also ecological
in relation to measuring socioeconomic status, since this
represents the socioeconomic characteristics of the
admitted individual’s area of residence, rather than the
personal characteristics of the admitted individual
(which were not available). However this is a widely-
used approach and SLAs are the smallest area for which
socioeconomic, health and population are available.
Differences could also have been masked by classifying
women into two SES groups rather than smaller groups
such as quintiles; however an initial analysis by SES
quintile also found very little difference between groups
(data not shown). Another limitation was the extent of
missing data on socioeconomic status prior to July 2006,
and on remoteness area prior to July 2005. In order to
address this, our primary analysis was restricted to use
data from July 2006 on, and admission rate ratios (which
used earlier years) were a secondary analysis. The find-
ings were consistent across both the primary and sec-
ondary analyses, however, and an additional sensitivity
analysis we undertook suggested that the subset we used
had not biased the results (Additional file 1).
As genital warts are predominantly managed in pri-
mary care or sexual health clinics [19], these admissions
data will only represent a fraction of warts cases. Admis-
sions involving a primary diagnosis of genital warts likely
represent more serious cases of warts which have not
responded to earlier treatment, or where surgical
treatment is not as readily available on an outpatient
basis. Admissions where warts were a contributing (but
not primary) diagnosis were generally for another purpose
(for example treatment of cervical abnormalities in
women, as previously described in the Methods). There-
fore, the absolute admission rates and variation in these
by SES and remoteness area could potentially relate to a
combination of access and behavioural issues; for example
a greater choice of treatment options outside hospitals in
major cities. As the main purpose of this analysis was to
examine whether the relative reduction (if any) in admis-
sion rates varied by SES, these potentially access-related
differences are not likely to affect our findings unless there
was a change in service usage unrelated to vaccination
during the same time period; however this seems unlikely
given that no changes were observed in older females.
Australia has had an organised, government-subsidised
cervical screening program in place since 1991, and yet,
while the program has been successful in reducing both
cervical cancer incidence and mortality, socioeconomic
and geographic disparities persist in cervical cancer [20].
Lower socioeconomic status is associated with lower
participation in cervical screening and higher cervical
cancer incidence and mortality [20]. Residing in outer
regional areas of Australia is associated with higher cer-
vical cancer mortality compared to more urban areas of
Australia [20] (but not incidence, suggesting treatment
variation may be a factor) [21]; while residing in remote
or very remote regions is associated with both higher
incidence and mortality [13]. In contrast, the uptake of
school-based HPV vaccination [3] and, as reported here,
its impact on genital warts, appears to have been rela-
tively equal across socioeconomic groups including in
different remoteness areas. This is potentially due to
high school-participation rates [22]; the relative ease of
vaccine administration (three doses) compared to re-
peated cervical cancer screening over many years; com-
paratively smaller (if any) out of pocket costs; and fewer
issues of access (which for example are potentially a factor
in poorer cancer survival in more remote areas) [21]. This
suggests that the school-based HPV vaccination program
in Australia may play an important role in reducing
disparities in cervical cancer, which exist even in the
context of an organised screening program and publicly-
subsidised healthcare more broadly. The finding of rela-
tively equal vaccine uptake in Australia [3, 4] is consistent
with data from other countries suggesting that school-
based programs result in more equitable uptake across
socioeconomic strata [23–26], implying our findings on
impact may also have relevance for other settings. It is
therefore very important to continue to monitor both
HPV vaccine uptake and impact in subgroups to ensure
that the results observed to date continue. It will also be
useful to assess the impact of HPV vaccination on cervical
Smith et al. BMC Infectious Diseases  (2016) 16:52 Page 9 of 11
abnormalities by socioeconomic status and remoteness area
to ascertain whether these findings for genital warts are also
observed in cervical cancer precursors; however as records
of cervical abnormalities on screening registers only include
women who attend for screening and screening attendance
varies by SES [13], this approach will have some limitations.
Therefore monitoring of genital warts in population sub-
groups is likely to continue to be useful, and will addition-
ally offer the opportunity to examine vaccine impact in
subgroups of males, who have been included in the HPV
vaccination program since 2013.
Conclusions
The relative reduction in genital warts since the imple-
mentation of the NHVP in Australia appears similar in
young females across different levels of disadvantage,
including within and outside major cities. The impact of
the program appears to have been relatively equal, both
for females predominantly vaccinated at school and in
the community, and also in terms of its indirect protec-
tion of males. Routinely-collected hospital admissions
data on genital warts are an important source of infor-
mation for ongoing monitoring of the impact of the
NHVP in subgroups and in males as, while undoubtedly
important in monitoring, data from cervical screening
registers will not completely fulfil this role.
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